|
Market Closed -
Euronext Paris
11:55:00 2026-09-04 EDT
|
5-day change | 1st Jan Change | ||
| 4.060 EUR | -1.22% |
|
+1.50% | +2.92% |
| 09-03 | Treatment period completed for Inventiva's NATiV3 study |  |
| 09-02 | Inventiva Says All Patients Completed 72-Week Treatment Period in Phase 3 Liver Disease Study | MT |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
Cash or Net Debt
- Stock Market
- Stocks
- IVA Stock
- Consensus Inventiva
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
